Methoxyphenyl maleamic acid augments the activity of cytotoxic drugs against murine tumours.
The anti-tumour effects of methoxyphenyl maleamic acid (MPMA) and cytotoxic drugs, in combination were investigated on P388 leukaemia and S180 (ascites) tumours. Simultaneous administration of MPMA with CTX or HN2 resulted in enhancement of anti-tumour activity. The increased activity was observed against P388 leukaemia, whereas S180 (ascites) tumour was not responsive to the combined treatment. The possible mechanism (s) of action, responsible for the modulation of activity of CTX and HN2 against P388 tumour have been postulated.
Indap
M A
MA
Cancer Research Institute, Tata Memorial Centre, Parel, Bombay, India.
Ambaye
R Y
RY
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001201:Ascites / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004357:Drug Synergism; D007941:Leukemia P388 / Q000188:drug therapy*; D008298:Maleates / Q000494:pharmacology*; D008466:Mechlorethamine / Q000008:administration & dosage; D051379:Mice
D008298:Maleates; D008466:Mechlorethamine; D003520:Cyclophosphamide